Lupin gets USFDA’s tentative approval for DETAF Tablets

31 Jan 2023 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets. This product would be manufactured at Lupin’s Nagpur facility in India. DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- & middle-income countries.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2209.90 14.90 (0.68%)
16-Jan-2026 11:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.55
Dr. Reddys Lab 1195.20
Cipla 1402.95
Zydus Lifesciences 884.55
Lupin 2209.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×